2-methylene-19-nor-vitamin D2 compounds
US7232810B2 · kind B2 · utility
12Cited by
11References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 2004 |
| Grant date | Jun 19, 2007 |
| Priority date | — |
| Expiry date | Aug 18, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C401/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
2-Methylene-19-nor-24(S) and 24(R) derivatives of 1α,25-dihydroxyvitamin D2 are disclosed. These compounds are characterized by minimal bone calcium mobilization activity and relatively high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment of diseases such as renal osteodystrophy, autoimmune diseases, and osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anticancer agents and for use treating skin diseases such as psoriasis
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.